Treatment strategy for advanced colorectal cancer

doi:10.3760/cma.j.issn.1673-422X.2016.05.018

Abstract

Abstract: At present, the main treatment methods of the patients with advanced colorectal cancer include surgery, chemotherapy, radiotherapy, targeted therapy, physical ablation and immunotherapy, but the chemotherapy is still the main treatment. The emergence of new chemotherapy drugs and the combination of radiotherapy, chemotherapy and targeted therapy in clinical have improved curative effect for the patients with advanced colorectal cancer. In order to better improve the quality of life, reduce side effects and obtain the best effect, now the individual multidisciplinary treatment has become an inevitable trend in the treatment of advanced colorectal cancer in clinical.

Key words: Colorectal neoplasms, Therapy, Drug therapy, Radiotherapy, Target therapy

Liu Debao, Xu Zhongfa, Fan Kaixi. Treatment strategy for advanced colorectal cancer[J]. Journal of International Oncology, 2016, 43(5): 387-390.

References

［1］ Chen W, Zheng R, Zhang S, et al. Annual report on status of cancer in China, 2010［J］. Chin J Cancer Res, 2014, 26(1): 48-58. DOI: 10.3978/j.issn.10009604.2014.01.08. ［2］ Chalya PL, McHembe MD, Mabula JB, et al. Clinicopathological patterns and challenges of management of colorectal cancer in a resourcelimited setting: a Tanzanian experience［J］. World J Surg Oncol, 2013, 11: 88. DOI: 10.1186/147778191188. ［3］ Courtney D, McDermott F, Heeney A, et al. Clinical review: surgical management of locally advanced and recurrent colorectal cancer［J］. Langenbecks Arch Surg, 2014, 339(1): 33-40. DOI: 10.1007/s004230131134x. ［4］宋天强. 结直肠癌肝转移的治疗进展［J］. 中国肿瘤临床, 2013, 40(4): 183-186. DOI: 10.3969/j.issn.10008179.2013.04.001. ［5］ Palumbo I, Piattoni S, Valentini V, et al. Gefitinib enhances the effects of combined radiotherapy and 5fluorouracil in a colorectal cancer cell line［J］. Int J Colorectal Dis, 2014, 29(1): 31-41. DOI: 10.1007/s0038401317541. ［6］ Kim JY, Kim YJ, Lee KW, et al. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage Ⅲ colon cancer: singlecenter study in Korea［J］. Jpn J Clin Oncol, 2013, 43(2): 132-138. DOI: 10.1093/jjco/hys195. ［7］ Jehn CF, Bning L, Krning H, et al. Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecanrefractory elderly patientswith metastatic colorectal cancer［J］. Eur J Cancer, 2014, 50(7): 1269-1275. DOI: 10.1016/j.ejca.2014.01.005. ［8］ MohelnikovaDuchonova B, Melichar B, Soucek P. FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy［J］. World J Gastroenterol, 2014, 20(30): 10316-10330. DOI: 10.3748/wjg.v20.i30.10316. ［9］ Folprecht G, Gruenberger T, Bechstein W, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)［J］. Ann Oncol, 2014, 25(5): 1018-1025. DOI: 10.1093/annonc/mdu088. ［10］刘慧龙, 王莉, 贾佳, 等. 奥沙利铂治疗结直肠癌相关神经毒性的临床观察及随访［J］. 中国肿瘤临床, 2013, 40(12): 725-729. DOI: 10.3969/j.issn.10008179.2013.12.011. ［11］ Wahba HA, ElHadaad HA, Roshdy S. Combination of irinotecan and 5fluorouracil with radiation in locally advanced rectal adenocarcinoma［J］. J Gastrointest Cancer, 2012, 43(3): 467-471. DOI: 10.1007/s1202901193505. ［12］ Jabbour SK, Patel S, Herman JM, et al. Intensitymodulated radiation therapy for rectal carcinoma can reduce treatment breaks and emergency department visits［J］. Int J Surg Oncol, 2012, 2012: 891067. DOI: 10.1155/2012/891067. ［13］ Mlcochova J, Faltejskova P, Nemecek R, et al. MicroRNAs targeting EGFR signalling pathway in colorectal cancer［J］. J Cancer Res Clin Oncol, 2013, 139(10): 1615-1624. DOI: 10.1007/s0043201314709. ［14］ Valverde A, Pearando J, Caas A, et al. Simultaneous inhibition of EGFR/VEGFR and cyclooxygenase2 targets stemnessrelated pathways in colorectal cancer cells［J］. PLoS One, 2015, 10(6): e0131363. DOI: 10.1371/journal.pone.0131363. ［15］ Cucchetti A, Piscaglia F, Cescon M, et al. Systematic review of surgical resection vs radiofrequency ablation for hepatocellular carcinoma［J］. World J Gastroenterol, 2013, 19(26): 4106-4118. DOI: 10.3748/wjg.v19.i26.4106. ［16］王俊峰, 郭志. 结肠癌肝转移物理消融治疗的新进展［J］. 中国肿瘤临床, 2014, 41(2): 142-146. DOI: 10.3969/j.issn.10008179.2014.02.20131179. ［17］ Solbiati L, Ahmed M, Cova L, et al. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate andlongterm survival with up to 10year followup［J］. Radiology, 2012, 265(3): 958-968. DOI: 10.1148/radiol.12111851. ［18］ Pernot S, Terme M, Voron T, et al. Colorectal cancer and immunity: what we know and perspectives［J］. World J Gastroenterol, 2014, 20(14): 3738-3750. DOI: 10.3748/wjg.v20.i14.3738. ［19］冯立波, 夏冬. 胃肠道恶性肿瘤免疫治疗的研究进展［J］. 中华临床医师杂志: 电子版, 2014, 8(3): 521-525. DOI: 10.3877/cma.j.issn.16740785.2014.03.036.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[4]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[5]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[6]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[7]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[8]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[9]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[10]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[11]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[12]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[13]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[14]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[15]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.